AMAZON BIOTECH TO LAUNCH PHASE II HIV TRIALS

A A

Amazon Biotech will begin Phase II clinical trials of its candidate AMZ0026 for the treatment of HIV.

The company has submitted to the FDA its protocol to test AMZ0026 as an antiviral and immunomodulating agent in non-treated HIV subjects.

The study design includes non-symptomatic HIV subjects who are not yet treated with highly active anti-retroviral therapy (HAART), with 50 percent of the subjects receiving placebo and 50 percent receiving AMZ0026. The six-month study will include the monitoring of T Cell increases and HIV plasma viral load decreases.